Scientists launch Triple-Threat attack on aggressive blood cancer
NCT ID NCT07341191
Summary
This study is testing whether adding two oral drugs (sonrotoclax and zanubrutinib) to a standard cell therapy (CAR-T) can better control a type of blood cancer called mantle cell lymphoma that has returned or stopped responding to prior treatments. It will enroll 40 adults who are already scheduled to receive CAR-T therapy. The goal is to see if this combination leads to a stronger and longer-lasting response against the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.